Cargando…
Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950952/ https://www.ncbi.nlm.nih.gov/pubmed/21206792 |
_version_ | 1782187671900127232 |
---|---|
author | Lalit, Vaya Appaya, Prakash M. Hegde, Rajendra P. Mital, Anukant K. Mittal, Sunil Nagpal, Rajesh Palaniappun, Vaiapuri Ramsubramaniam, C. Rao, Gundugurti P. Roy, Krishna Trivedi, Jitendra K. Vankar, Ganpat K. Karan, Rajesh S. Shah, Sweety Patel, Ronak B. |
author_facet | Lalit, Vaya Appaya, Prakash M. Hegde, Rajendra P. Mital, Anukant K. Mittal, Sunil Nagpal, Rajesh Palaniappun, Vaiapuri Ramsubramaniam, C. Rao, Gundugurti P. Roy, Krishna Trivedi, Jitendra K. Vankar, Ganpat K. Karan, Rajesh S. Shah, Sweety Patel, Ronak B. |
author_sort | Lalit, Vaya |
collection | PubMed |
description | The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of > 18 were randomly assigned to citalopram, 20–40 mg/day (74 patients), escitalopram, 10–20 mg/day (69 patients) and sertraline, 50-150 mg/day (71 patients), for a 4-week double-blind treatment period, with dosage adjustment (after 2 weeks of treatment) according to the response to treatment. Clinical response was evaluated by the 17 items HAM-D and the Clinical Global Impression (CGI) scales, which were recorded at baseline and at weekly intervals. Tolerability was evaluated by observed/spontaneously reported adverse changes in laboratory parameters (baseline and after 4 weeks). Response rate was defined as a decrease in HAM-D score by 50% from baseline and remission rate was defined as a HAM-D score of < 8. Response rate at the end of two week were 58% for escitalopram (10mg/day), 49% for citalopram (20mg/day) and 52% for sertraline (50-100mg/day). Response rate at the end of four week were 90% for escitalopram (10-20mg/day), 86% for citalopram (20-40mg/day) and 97% for sertraline (100-150mg/day). The Remission rates at the end of four weeks were 74% for escitalopram, 65% for citalopram and 77% for sertraline. Adverse experiences were reported by 45% of patients in escitalopram group, 58% patients in citalopram and 56% patients in the sertraline group. Additionally, there were lesser dropouts and lesser requirement for dose escalation in escitalopram than in citalopram and sertraline group. In conclusion Escitalopram, the Senantiomer of the citalopram is a safe and effective antidepressant in the Indian population. It has potentially superior efficacy than citalopram and a comparable efficacy to sertraline with fewer side effects than both citalopram and sertraline. |
format | Text |
id | pubmed-2950952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-29509522011-01-04 Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression Lalit, Vaya Appaya, Prakash M. Hegde, Rajendra P. Mital, Anukant K. Mittal, Sunil Nagpal, Rajesh Palaniappun, Vaiapuri Ramsubramaniam, C. Rao, Gundugurti P. Roy, Krishna Trivedi, Jitendra K. Vankar, Ganpat K. Karan, Rajesh S. Shah, Sweety Patel, Ronak B. Indian J Psychiatry Original Article The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of > 18 were randomly assigned to citalopram, 20–40 mg/day (74 patients), escitalopram, 10–20 mg/day (69 patients) and sertraline, 50-150 mg/day (71 patients), for a 4-week double-blind treatment period, with dosage adjustment (after 2 weeks of treatment) according to the response to treatment. Clinical response was evaluated by the 17 items HAM-D and the Clinical Global Impression (CGI) scales, which were recorded at baseline and at weekly intervals. Tolerability was evaluated by observed/spontaneously reported adverse changes in laboratory parameters (baseline and after 4 weeks). Response rate was defined as a decrease in HAM-D score by 50% from baseline and remission rate was defined as a HAM-D score of < 8. Response rate at the end of two week were 58% for escitalopram (10mg/day), 49% for citalopram (20mg/day) and 52% for sertraline (50-100mg/day). Response rate at the end of four week were 90% for escitalopram (10-20mg/day), 86% for citalopram (20-40mg/day) and 97% for sertraline (100-150mg/day). The Remission rates at the end of four weeks were 74% for escitalopram, 65% for citalopram and 77% for sertraline. Adverse experiences were reported by 45% of patients in escitalopram group, 58% patients in citalopram and 56% patients in the sertraline group. Additionally, there were lesser dropouts and lesser requirement for dose escalation in escitalopram than in citalopram and sertraline group. In conclusion Escitalopram, the Senantiomer of the citalopram is a safe and effective antidepressant in the Indian population. It has potentially superior efficacy than citalopram and a comparable efficacy to sertraline with fewer side effects than both citalopram and sertraline. Medknow Publications 2004 /pmc/articles/PMC2950952/ /pubmed/21206792 Text en Copyright: © Indian Journal of Psychiatry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lalit, Vaya Appaya, Prakash M. Hegde, Rajendra P. Mital, Anukant K. Mittal, Sunil Nagpal, Rajesh Palaniappun, Vaiapuri Ramsubramaniam, C. Rao, Gundugurti P. Roy, Krishna Trivedi, Jitendra K. Vankar, Ganpat K. Karan, Rajesh S. Shah, Sweety Patel, Ronak B. Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression |
title | Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression |
title_full | Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression |
title_fullStr | Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression |
title_full_unstemmed | Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression |
title_short | Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression |
title_sort | escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in indian patients with unipolar major depression |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950952/ https://www.ncbi.nlm.nih.gov/pubmed/21206792 |
work_keys_str_mv | AT lalitvaya escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT appayaprakashm escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT hegderajendrap escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT mitalanukantk escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT mittalsunil escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT nagpalrajesh escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT palaniappunvaiapuri escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT ramsubramaniamc escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT raogundugurtip escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT roykrishna escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT trivedijitendrak escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT vankarganpatk escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT karanrajeshs escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT shahsweety escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression AT patelronakb escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression |